The University of Chicago Header Logo

Connection

Stanley Liauw to Aged

Back to Details
This is a "connection" page, showing publications Stanley Liauw has written about Aged.
Stanley Liauw
Connection Strength
1.575
Aged
  1. Long-term patient-reported outcomes and toxicity following salvage radiotherapy for biochemical recurrence after radical prostatectomy. Cancer. 2026 Sep 15; 132(18):e70609.
    View in: PubMed
    Score: 0.068
  2. A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2026 05 01; 125(1):164-170.
    View in: PubMed
    Score: 0.062
  3. Online correction of intrafraction motion during volumetric modulated arc therapy for prostate radiotherapy using fiducial-based kV imaging: A cohort study quantifying the frequency of shifts and analysis of men at highest risk. J Appl Clin Med Phys. 2025 Apr; 26(4):e14603.
    View in: PubMed
    Score: 0.061
  4. Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 08; 22(4):102103.
    View in: PubMed
    Score: 0.058
  5. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245.
    View in: PubMed
    Score: 0.049
  6. A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640.
    View in: PubMed
    Score: 0.047
  7. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
    View in: PubMed
    Score: 0.045
  8. Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression. Cancer Med. 2020 07; 9(13):4667-4675.
    View in: PubMed
    Score: 0.044
  9. PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. Urol Oncol. 2020 06; 38(6):600.e1-600.e8.
    View in: PubMed
    Score: 0.043
  10. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019 11; 76(5):686-692.
    View in: PubMed
    Score: 0.041
  11. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18.
    View in: PubMed
    Score: 0.039
  12. Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. Urol Oncol. 2018 10; 36(10):471.e11-471.e18.
    View in: PubMed
    Score: 0.039
  13. Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. PLoS One. 2018; 13(3):e0194234.
    View in: PubMed
    Score: 0.038
  14. External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):740-746.
    View in: PubMed
    Score: 0.035
  15. Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urol Oncol. 2016 09; 34(9):416.e15-21.
    View in: PubMed
    Score: 0.033
  16. Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):1031-9.
    View in: PubMed
    Score: 0.032
  17. Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes. PLoS One. 2015; 10(10):e0141639.
    View in: PubMed
    Score: 0.032
  18. Image-guided radiation therapy for prostate cancer: A computed tomography-based assessment of fiducial marker migration between placement and 7 days. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):241-7.
    View in: PubMed
    Score: 0.030
  19. The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 May-Jun; 5(3):e223-e228.
    View in: PubMed
    Score: 0.030
  20. Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. Cancer Med. 2014 Aug; 3(4):954-61.
    View in: PubMed
    Score: 0.029
  21. Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. Cancer. 2013 Aug 01; 119(15):2807-14.
    View in: PubMed
    Score: 0.027
  22. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology. 2013 Jun; 81(6):1196-201.
    View in: PubMed
    Score: 0.027
  23. Radiation dose =54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiat Oncol. 2012 Sep 13; 7:156.
    View in: PubMed
    Score: 0.026
  24. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012 Oct 01; 30(28):3540-4.
    View in: PubMed
    Score: 0.026
  25. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.
    View in: PubMed
    Score: 0.025
  26. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol. 2012 Aug; 19(8):2471-6.
    View in: PubMed
    Score: 0.025
  27. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):235-41.
    View in: PubMed
    Score: 0.023
  28. Prolongation of total treatment time because of infrequently missed days of treatment is not associated with inferior biochemical outcome after dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):751-7.
    View in: PubMed
    Score: 0.023
  29. External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS). Int J Radiat Oncol Biol Phys. 2011 Jul 15; 80(4):1080-6.
    View in: PubMed
    Score: 0.022
  30. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Mar 15; 79(4):1022-8.
    View in: PubMed
    Score: 0.022
  31. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
    View in: PubMed
    Score: 0.022
  32. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010 Apr 01; 116(7):1820-6.
    View in: PubMed
    Score: 0.022
  33. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1060-5.
    View in: PubMed
    Score: 0.021
  34. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis. Brachytherapy. 2010 Apr-Jun; 9(2):131-6.
    View in: PubMed
    Score: 0.021
  35. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30.
    View in: PubMed
    Score: 0.021
  36. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat. 2009 Jun; 8(3):201-6.
    View in: PubMed
    Score: 0.021
  37. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):755-60.
    View in: PubMed
    Score: 0.021
  38. Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1316-21.
    View in: PubMed
    Score: 0.019
  39. Whole-abdomen radiotherapy for non-Hodgkin's lymphoma using twice-daily fractionation. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1440-5.
    View in: PubMed
    Score: 0.017
  40. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):669-73.
    View in: PubMed
    Score: 0.017
  41. Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response. J Surg Oncol. 2026 Jun; 133(8):1016-1022.
    View in: PubMed
    Score: 0.017
  42. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol. 2006 Mar 20; 24(9):1421-7.
    View in: PubMed
    Score: 0.016
  43. Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial. Clin Cancer Res. 2026 Feb 04; 32(3):479-488.
    View in: PubMed
    Score: 0.016
  44. Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 07 01; 11(7):726-734.
    View in: PubMed
    Score: 0.016
  45. Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study. Pract Radiat Oncol. 2025 Jul-Aug; 15(4):e350-e361.
    View in: PubMed
    Score: 0.015
  46. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
    View in: PubMed
    Score: 0.014
  47. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology. 2003 Jun; 61(6):1204-10.
    View in: PubMed
    Score: 0.014
  48. Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021 03 15; 109(4):953-963.
    View in: PubMed
    Score: 0.011
  49. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer. 2019 Jun 13; 19(1):572.
    View in: PubMed
    Score: 0.010
  50. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. Am J Clin Oncol. 2019 04; 42(4):382-390.
    View in: PubMed
    Score: 0.010
  51. Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome. Br J Haematol. 2019 07; 186(2):377-379.
    View in: PubMed
    Score: 0.010
  52. Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):304-313.
    View in: PubMed
    Score: 0.010
  53. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 05 10; 4(5):e175230.
    View in: PubMed
    Score: 0.010
  54. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2017 Dec; 40(6):612-620.
    View in: PubMed
    Score: 0.009
  55. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol. 2018 07; 74(1):99-106.
    View in: PubMed
    Score: 0.009
  56. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352.
    View in: PubMed
    Score: 0.009
  57. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288.
    View in: PubMed
    Score: 0.009
  58. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053.
    View in: PubMed
    Score: 0.008
  59. Combined-modality therapy for rectal cancer: analysis of potential differences in disease presentation, treatment adherence, and treatment outcome according to race. Am J Clin Oncol. 2014 Apr; 37(2):122-5.
    View in: PubMed
    Score: 0.007
  60. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. PLoS One. 2014; 9(1):e82642.
    View in: PubMed
    Score: 0.007
  61. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95.
    View in: PubMed
    Score: 0.007
  62. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1473-9.
    View in: PubMed
    Score: 0.006
  63. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol. 2010 Dec; 33(6):619-23.
    View in: PubMed
    Score: 0.006
  64. Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol. 2008 Aug; 31(4):375-8.
    View in: PubMed
    Score: 0.005
  65. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. 2008 Dec; 72(6):1298-302; discussion 1302-4.
    View in: PubMed
    Score: 0.005
  66. Lymph node-positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection? Cancer. 2008 Mar 01; 112(5):1076-82.
    View in: PubMed
    Score: 0.005
  67. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007 Oct 10; 25(29):4581-6.
    View in: PubMed
    Score: 0.005
  68. Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer Prostatic Dis. 2007; 10(4):347-51.
    View in: PubMed
    Score: 0.004
  69. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004 Mar 17; 291(11):1325-32.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.